<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528994</url>
  </required_header>
  <id_info>
    <org_study_id>2014D001170</org_study_id>
    <nct_id>NCT02528994</nct_id>
  </id_info>
  <brief_title>Short Term Dietary Serine Supplementation and Circulating Serine Levels</brief_title>
  <official_title>A Pilot Study to Test the Effect of Short Term Dietary Serine Supplementation on Circulating Serine Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the effect of short-term, high-dose dietary serine supplementation on&#xD;
      circulating levels of serine. Individuals with risk factors for type 2 diabetes will be&#xD;
      recruited into the 2 week study. Effects of dietary serine supplementation on glycemic&#xD;
      measures will also be explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, randomized, nutritional intervention study in adults.&#xD;
      Subjects will have three visits to the Massachusetts General Hospital Clinical Research&#xD;
      Center (CRC) during the 2 week study.&#xD;
&#xD;
      At the first study visit (Visit 1), the following will occur: informed consent; medical and&#xD;
      nutritional history assessment; blood pressure, weight and height, fasting blood draw and&#xD;
      blood work during a 2 hr oral glucose tolerance test; explanation and instructions for&#xD;
      completion of a 4-day food log; randomized assignment to dose of dietary serine&#xD;
      supplementation (6g, 12g, 24g, or 48g); provide 7 days of dietary serine supplements; take&#xD;
      first dose of supplement with snack; schedule Visit 2 and Visit 3.&#xD;
&#xD;
      Between Visit 1 and Visit 2, participants will complete the Food Log and take the assigned&#xD;
      dose of dietary serine supplementation 3 times daily.&#xD;
&#xD;
      Visit 2 will occur 7 days after Visit 1. Subjects will not take dietary serine&#xD;
      supplementation prior to Visit 2 activities. At Visit 2, the following will occur: weight and&#xD;
      blood pressure; fasting blood draw; administration of assigned dose of dietary serine&#xD;
      supplementation with snack after blood work; review of the 4-day food log; provide 7 days of&#xD;
      dietary serine supplements completion of anonymous survey to assess tolerability of&#xD;
      supplement. Participants will continue to take the assigned dose of dietary serine&#xD;
      supplementation 3 times daily between Visit 2 and Visit 3.&#xD;
&#xD;
      Visit 3 will occur 7 days after Visit 2. At Visit 3, the following will occur: weight and&#xD;
      blood pressure; review of the 4-day food log; fasting blood draw and blood work during a 2 hr&#xD;
      oral glucose tolerance test; completion of study survey to assess tolerability of the&#xD;
      supplement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The PI will be leaving the institution and not continuing the study&#xD;
  </why_stopped>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating serine levels</measure>
    <time_frame>14 days</time_frame>
    <description>We will measure circulating serine levels after 14 days of intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Supplement tolerability</measure>
    <time_frame>14 days</time_frame>
    <description>We will assess tolerability of dietary serine supplements after 14 days of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting and post-prandial glucose</measure>
    <time_frame>14 days</time_frame>
    <description>We will assess fasting and post-prandial glucose after 14 days of intervention</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Serine</condition>
  <arm_group>
    <arm_group_label>Serine 6g daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized participants will take 6g daily of dietary serine supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serine 12g daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized participants will take 12g daily of dietary serine supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serine 24g daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized participants will take 24g daily of dietary serine supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serine 48g daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized participants will take 48g daily of dietary serine supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-serine</intervention_name>
    <description>Participants will take dietary serine supplementation daily</description>
    <arm_group_label>Serine 12g daily</arm_group_label>
    <arm_group_label>Serine 24g daily</arm_group_label>
    <arm_group_label>Serine 48g daily</arm_group_label>
    <arm_group_label>Serine 6g daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  risk factors for type 2 diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known type 2 diabetes&#xD;
&#xD;
          -  women who are pregnant, nursing, or not using contraception or abstinence&#xD;
&#xD;
          -  taking amino acid supplements during the study or at any time 1 month prior to&#xD;
             enrollment in the study&#xD;
&#xD;
          -  conditions causing intestinal malabsorption, including celiac disease or a history of&#xD;
             intestinal or gastric bypass surgery&#xD;
&#xD;
          -  known active liver disease&#xD;
&#xD;
          -  currently taking or intending to take during the study duration any medication known&#xD;
             to affect glycemic parameters, such as glucocorticoids, growth hormone, or&#xD;
             fluoroquinolones&#xD;
&#xD;
          -  participation in any other interventional study during the study duration&#xD;
&#xD;
          -  inability to adhere to study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey A Walford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Geoffrey Walford, MD</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Dietary supplements</keyword>
  <keyword>Metabolism</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

